Business
PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune®-Based T-Cell Inducing COVID-19 Vaccine
Brazilian-based Blanver brings depth of expertise in development and commercialization of innovative pharmaceuticals across Latin America FLORHAM PARK, N.J.,
About this update from Pds Biotechnology Corporation
[{"type":"text","content":"Brazilian-based Blanver brings depth of expertise in development and commercialization of innovative pharmaceuticals across Latin America\nFLORHAM PARK, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, and Farmacore Biotechnology today announced that Blanver Farmoquímica e Farmacêutica S.A. has joined their consortium to develop and commercialize a novel COVID-19 vaccine in Latin America. Blanver is a leading Brazilian Pharmaceutical Company focused on the development, manufacture, and commercialization of innovative pharmaceutical products. Under the terms of the agreement, São Paulo-based Blanver will manufacture, promote, distribute, and commercialize the Versamune®-based COVID-19 vaccine in Latin America. As the license holder of Versamune-CoV2-FC (PDS0203) in Latin America, Farmacore will continue to lead the regulatory and clinical trial efforts in Brazil and has selected a top clinical research organization to conduct clinical trials in Brazil. PDS Biotech will continue to contribute scientific expertise and operational support. “Innovation is part of Blanver’s DNA,” commented Sergio Frangioni, Blanver Group CEO. “We are honored to join the consortium with PDS Biotech and Farmacore as our partners in Latin America to advance this innovative treatment to patients quickly in the fight against this deadly disease.” “We are delighted to have these two expert partners in Latin America, who provide a combination of scientific and manufacturing expertise in addition to local market experience to help broaden the potential reach of a Versamune®-based COVID-19 vaccine to patients,” said Dr. Frank Bedu-Addo, CEO of PDS Biotech. “We are excited to add Blanver’s wealth of experience in development and commercialization across Latin America to this consortium as we continue in the fight against this global pandemic,” said Helena Faccioli, CEO of Farmacore. The consortium is in active discussions with specific agencies of the Brazilian government to extend the preclinical funding to cover the upcoming human clinical trials anticipated to begin during the first half of 2021. The novel vaccine combines PDS Biotech’s Versamu...